Site Sponsors
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD

There is 1 related live offer.

Save 25% on magneTherm

NanoViricides CEO to Speak at NanoBio 2009

Published on June 22, 2009 at 7:27 AM

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), a development stage company that is creating special purpose nanomaterials for viral therapy, announced today that its CEO, Dr. Eugene Seymour, has been invited to present a talk, and, in addition, participate in presenting a workshop on "Nanoparticle Formulation: principles and applications", at the 3rd International Congress of NanoBiotechnology + NanoMedicine (NanoBio 2009) to be held in San Francisco on June 22-24, 2009. The website for the event is http://www.ianano.org. The conference is sponsored by, among others, The National Cancer Institute, the National Institute of Standards and Technology, the Lawrence Berkeley National Laboratory and Stanford University.

Dr Seymour plans to discuss the nature of the Company’s nanoviricide™ drug technology and platform as well as results of various laboratory and animal studies against different viruses. Dr. Seymour will summarize the Company’s successes against multiple types of influenza viruses including different H5N1 bird flu viruses and H1N1 virus similar to the current pandemic-causing H1N1. He will also talk about the Company’s successes against HIV, adenoviral epidemic keratoconjunctivitis (EKC), Ebola and Rabies. In addition to these programs, the Company is also developing nanoviricide drugs against dengue viruses. His talk is scheduled for Tuesday, the 23rd June, 2009. The workshop takes place in two sessions on Monday, the 22nd.

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit